Traws Pharma Inc. held a Special Meeting of Stockholders on February 17, 2025, where stockholders approved the issuance of more than 19.99% of outstanding shares related to Pre-Funded Warrants and Series A Warrants, with 65.6% of shares represented at the meeting.